BGM0504
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
BrightGene Bio-Medical Technology Co · Phase 2 · Recruiting · Enrollment 200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| The dose1 group | Obesity, no T2D | n/r | 20 | n/r | n/r |
| The dose2 group | Obesity, no T2D | n/r | 20 | n/r | n/r |
| The dose3 group | Obesity, no T2D | n/r | 20 | n/r | n/r |
| The dose4 group | Obesity, no T2D | n/r | 20 | n/r | n/r |
| Placebo group | Obesity, no T2D | n/r | 20 | n/r | n/r |